Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration‐Resistant Prostate Cancer (mCRPC)

BACKGROUND. Enhancing the effectiveness of docetaxel for men with metastatic castration‐resistant prostate cancer (mCRPC) is an unmet clinical need. Preclinical studies demonstrated that high‐dose pantoprazole can prevent or delay resistance to docetaxel via the inhibition of autophagy in several so...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncologist
Prif Awduron: Hansen, Aaron R., Tannock, Ian F., Templeton, Arnoud, Chen, Eric, Evans, Andrew, Knox, Jennifer, Prawira, Amy, Sridhar, Srikala S., Tan, Susie, Vera‐Badillo, Francisco, Wang, Lisa, Wouters, Bradly G., Joshua, Anthony M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons, Inc. 2019
Pynciau:
Genitourinary Cancer
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738292/
https://ncbi.nlm.nih.gov/pubmed/30952818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0621
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg